Guo Yuanhui, Shen Baixuan, Lou Chaoxuan, Wang Li, Li Ying
Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, 471003, China.
Department of Pharmacy, The First Affiliated Hospital, College of Clinical Medicine of Henan University of Science and Technology, Luoyang, 471003, China.
Discov Oncol. 2024 Oct 29;15(1):599. doi: 10.1007/s12672-024-01483-2.
Hepatocellular carcinoma (HCC) is a highly heterogeneous malignancy with poor prognosis and a common cause of cancer-related death worldwide, and despite ongoing therapeutic breakthroughs, patient survival benefits are limited. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of coronavirus disease 2019 (COVID-19) and poses a major threat to humanity worldwide. As the epidemic continues to develop, more and more people are infected with SARS-CoV-2, including patients with HCC. However, the relationship between COVID-19 and HCC has not yet been fully elucidated. Our study aimed to identify the shared genetic characteristics and molecular mechanisms between COVID-19 and HCC. The data involved in this study come from Gene Expression Omnibus (GEO), The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression(GTEx), and Cancer Cell Line Encyclopedia(CCLE) databases. We used differentially expressed genes to perform enrichment analysis to reveal the biological landscape of COVID-19 combined with HCC. In addition, weighted gene co-expression network analysis (WGCNA) was used to study the co-expression network related to COVID-19 and HCC. We then combined the validation datasets to screen out immunoglobulin superfamily member 1 (IGSF1) as the most important core gene. Finally, we extensively studied the functional expression of IGSF1 in tumor samples, normal tissues, and cancer cell lines. The molecular mechanisms related to COVID-19 and HCC are rarely studied. Our study identifies IGSF1 as a potential therapeutic target and immune-related biomarker for patients with COVID-19 and HCC.
肝细胞癌（HCC）是一种高度异质性的恶性肿瘤，预后较差，是全球癌症相关死亡的常见原因，尽管治疗上不断有突破，但患者的生存获益仍然有限。严重急性呼吸综合征冠状病毒2（SARS-CoV-2）是2019冠状病毒病（COVID-19）的病原体，对全球人类构成重大威胁。随着疫情的持续发展，越来越多的人感染了SARS-CoV-2，包括HCC患者。然而，COVID-19与HCC之间的关系尚未完全阐明。我们的研究旨在确定COVID-19与HCC之间共同的遗传特征和分子机制。本研究涉及的数据来自基因表达综合数据库（GEO）、癌症基因组图谱（TCGA）、基因型-组织表达数据库（GTEx）和癌细胞系百科全书（CCLE）。我们使用差异表达基因进行富集分析，以揭示COVID-19合并HCC的生物学特征。此外，加权基因共表达网络分析（WGCNA）用于研究与COVID-19和HCC相关的共表达网络。然后，我们结合验证数据集筛选出免疫球蛋白超家族成员1（IGSF1）作为最重要的核心基因。最后，我们广泛研究了IGSF1在肿瘤样本、正常组织和癌细胞系中的功能表达。与COVID-19和HCC相关的分子机制很少被研究。我们的研究确定IGSF1是COVID-19和HCC患者潜在的治疗靶点和免疫相关生物标志物。
